SCHEMBL1069006

SCHEMBL1069006

O=C(O)N1CCCC(CCCO)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.40
NPC1 O15118 2/20 0.38
NR2F2 P24468 1/20 0.38
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
EPHX2 P34913 5/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPK1 P28482 1/20 0.34
MEN1 O00255 2/20 0.34
POLB P06746 2/20 0.34
KMT2A Q03164 2/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 1/20 0.33
LIPE Q05469 1/20 0.33
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
GRM3 Q14832 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16528800 1.00 AKR1C3 (0.40) AKR1C3NPC1NR2F2ITGB3ITGA2B
SCHEMBL26619830 0.95 AKR1C3 (0.40) AKR1C3NPC1NR2F2ITGB3ITGA2B
SCHEMBL26619658 0.95 AKR1C3 (0.40) AKR1C3NPC1NR2F2ITGB3ITGA2B
SCHEMBL26619637 0.95 AKR1C3 (0.40) AKR1C3NPC1NR2F2ITGB3ITGA2B
SCHEMBL1710707 0.89 AKR1C3 (0.48) AKR1C3NPC1ITGB3ITGA2BEPHX2
SCHEMBL22983193 0.89 ITGB3 (0.39) AKR1C3ITGB3ITGA2B
SCHEMBL26619704 0.89 ITGB3 (0.39) AKR1C3ITGB3ITGA2B
SCHEMBL20590848 0.89 AKR1C3 (0.48) AKR1C3NPC1ITGB3ITGA2BEPHX2
SCHEMBL4516909 0.89 AKR1C3 (0.48) AKR1C3NPC1ITGB3ITGA2BEPHX2
SCHEMBL16528062 0.85 ITGB3 (0.48) AKR1C3ITGB3ITGA2BKDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268285-B1 THERAPEUTIC COMPOUNDS MERCK SHARP & DOHME (US) 2018-06-27 EP disclosed
US-8591878-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-11-26 US disclosed
US-20110002884-A1 THERAPEUTIC COMPOUNDS MERCK SHARP & DOHME LLC 2011-01-06 US disclosed
EP-2268285-A1 THERAPEUTIC COMPOUNDS Merck Sharp & Dohme Corp. (US) 2011-01-05 EP disclosed
WO-2009108507-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2009-09-03 WO disclosed
CN-1021328-C PROCESS FOR PREPARING PYRIDAZINAMINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 1993-06-23 CN disclosed
CN-1033274-A The preparation method of new Pyridazinyl amine derivative JANSSEN PHARMACEUTICA NV (BE) 1989-06-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002884-A1 THERAPEUTIC COMPOUNDS RRP1B, ZC3HAV1, RNASE1 AKR1C3 275/4885NPC1 554/4885NR2F2 2945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.